- Home
- IONS vs JBTM Comparison
IONS vs JBTM Comparison
Compare IONS & JBTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- JBTM
- Stock Information
- Founded
- IONS 1989
- JBTM 1994
- Country
- IONS United States
- JBTM United States
- Employees
- IONS N/A
- JBTM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- JBTM
- Sector
- IONS Health Care
- JBTM
- Exchange
- IONS Nasdaq
- JBTM Nasdaq
- Market Cap
- IONS 6.9B
- JBTM 6.9B
- IPO Year
- IONS 1991
- JBTM N/A
- Fundamental
- Price
- IONS $43.78
- JBTM $138.61
- Analyst Decision
- IONS Buy
- JBTM Strong Buy
- Analyst Count
- IONS 14
- JBTM 2
- Target Price
- IONS $58.43
- JBTM $143.00
- AVG Volume (30 Days)
- IONS 2.0M
- JBTM 544.2K
- Earning Date
- IONS 07-30-2025
- JBTM 08-04-2025
- Dividend Yield
- IONS N/A
- JBTM 0.29%
- EPS Growth
- IONS N/A
- JBTM N/A
- EPS
- IONS N/A
- JBTM N/A
- Revenue
- IONS $944,050,000.00
- JBTM $2,710,300,000.00
- Revenue This Year
- IONS $9.21
- JBTM $117.13
- Revenue Next Year
- IONS $14.35
- JBTM $4.51
- P/E Ratio
- IONS N/A
- JBTM N/A
- Revenue Growth
- IONS 16.05
- JBTM 64.98
- 52 Week Low
- IONS $23.95
- JBTM $82.64
- 52 Week High
- IONS $50.43
- JBTM $145.64
- Technical
- Relative Strength Index (RSI)
- IONS 60.61
- JBTM N/A
- Support Level
- IONS $40.37
- JBTM N/A
- Resistance Level
- IONS $41.93
- JBTM N/A
- Average True Range (ATR)
- IONS 1.42
- JBTM 0.00
- MACD
- IONS -0.03
- JBTM 0.00
- Stochastic Oscillator
- IONS 66.61
- JBTM 0.00
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About JBTM JBT Marel Corporation
JBT Marel Corp is a technology solutions provider to segments of the food and beverage industry. It designs, produces, and services products and systems for a broad range of end markets, generating roughly one-half of annual revenue from recurring parts, services, rebuilds, and leasing operations.